Sir-We are indebted to Davis et al. [1] for their valuable study, which strengthens the role of active surveillance. The followup period of 12 months is laudable, because infections detected after a patient's discharge from the hospital could also be observed.
One important and very alarming finding in the study [1] is that 2.7%-4.4% of patients in the studied population were infected with methicillin-resistant Staphylococcus aureus (MRSA) during their hospitalization, regardless of their colonization status. Also alarming is the higher risk of MRSA infection for noncolonized patients, compared with colonized patients, in the intensive care units of surgical and trauma departments. Only one-third of MRSA infections occurred in patients who were previously colonized with MRSA. Two-thirds of MRSA infections are apparently acquired via transmission. This is a strong argument for the roles of active surveillance, contact isolation precautions, and hand hygiene (the utility of the latter has recently and repeatedly been questioned). A systematic review has shown moderate evidence for a preventive effect of isolation precautions [2] , but we postulate that concerted use of these precautions could have prevented, at least partially, the morbidity and mortality associated with 19 MRSA infections reported in Davis et al. [1] . We would like to obtain more information on the use of barrier precautions and hand hygiene in the institution discussed in Davis et al. [1] .
There are 4 additional comments that we wish to make. First, the rate of MRSA prevalence is generally defined in the literature as the proportion of all S. aureus isolates that are methicillin resistant. Thus, the actual rate of MRSA in the study population would be 15.9% of isolates (26 MRSA isolates out of 163 S. aureus isolates), rather than the 3.4% of isolates reported by Davis et al. [1] .
Second, the question of whether MRSA is more virulent than methicillin-susceptible S. aureus (MSSA) cannot be answered by comparing the incidence rates of MRSA infection in patients who are colonized with either MSSA or MRSA. Ideally, the rate of MSSA infection in patients who are colonized with MSSA would have been compared with the rate of MRSA infection in those who are colonized with MRSA. The latter figure is reported as 19%, but how many patients with MSSA colonization acquire MSSA infection? Wertheim et al. [3] have recently reported a relative risk of 3.0 for MSSA bacteremia in MSSA carriers. A case-case-control study design, as shown by Kaye et al. [4] , would answer this question, because risk factors for infection might be different in the 3 groups (MSSA, MRSA, or no colonization).
Third, the use of susceptibility patterns to determine whether MRSA strains are nosocomial or community-acquired strains seems somewhat outdated. Modern molecular techniques for making this determination are available, including PFGE for strain typing and epidemiological analysis [5] and PCR for determination of the mecA genetic element and virulence factors associated with community-acquired strains [6] . It is not clear whether the infections in noncolonized patients originate from patients with MRSA colonization or from another source.
Finally, Davis et al. [1] used only swabs of the nares to determine colonization status. Adding cultures of the throat, as is common in epidemiological studies, would have increased the sensitivity of testing [7] and thus changed the statistical significance of the findings.
In conclusion, the findings of Davis et al. [1] 
Reply to Tietz et al.
Sir-We appreciate the comments on our recent article [1] by Tietz et al. [2] and would like to address some of the issues they raise. In accordance with the most recently published guidelines by the Society for Healthcare Epidemiology of America (SHEA) for the prevention of nosocomial transmission of multidrugresistant Staphylococcus aureus [3] , patients admitted to our facility who are colonized or infected with methicillinresistant S. aureus (MRSA) are placed in contact isolation, and strict hand hygiene is encouraged of all health care personnel who have contact with patients. Tietz et al. [2] questioned the utility of including samples of the pharynx to increase the sensitivity of testing for MRSA colonization. The findings of previous studies by our group [4, 5] and others [6, 7] , in addition to the previously mentioned SHEA guidelines, support the sampling of only the nares to assess for MRSA colonization. On this basis, we are confident that very few subjects who were colonized with MRSA were not identified during our investigation, and we doubt that obtaining samples from multiple sites would have yielded significantly different results. Tietz et al. [2] point out that two-thirds of the absolute number of MRSA infections occurred in patients who were not colonized with MRSA. Although this is correct, the appropriate evaluation of the data, as we reported [1] , is the discordance in the rates of MRSA infection among the different patient populations studied. The incidence of MRSA infection was significantly higher among patients who were colonized with MRSA (19% of colonized patients) than among patients who were not colonized with MRSA (1.9% of noncolonized patients). Furthermore, patients who were found to be colonized with MRSA at admission were more likely to develop infection during the hospitalization in which MRSA colonization was identified than during a future hospitalization. The patients who developed MRSA infection but who were not colonized with MRSA at admission were more likely to develop infection during a future hospitalization. Although our study [1] did not specifically address the question of increased virulence of MRSA compared with that of methicillin-susceptible S. aureus (MSSA), there is increasing evidence that community-acquired MRSA may be more virulent. Another recent report by our group [8] demonstrated a higher rate of soft-tissue infection in subjects colonized with community-acquired MRSA, compared with subjects colonized with MSSA or not colonized with S. aureus. The findings of that study [8] and others [9] add to the growing evidence that most community-acquired MRSA isolates now express a specific exotoxin, encoded by the Panton-Valentine leukocidin gene, that is likely to be responsible for increased virulence.
The role of MRSA eradication in reducing the rates of subsequent MRSA infection of MRSA-colonized patients and in decreasing the transmission of MRSA in health care facilities needs to be adequately addressed. We are currently pursuing these questions with a randomized, double-blind, placebo-controlled study to determine the effect of topical mupirocin when used to eradicate MRSA colonization of nares identified at admission to the intensive care unit. Our hypothesis is that MRSA eradication will decrease the rate of subsequent MRSA infection in these patients. If true, this would significantly decrease the negative impact that MRSA infection has on hospitalized patients.
